First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis

David Price, Marc Miravitlles, Ian Pavord, Mike Thomas, Jadwiga Wedzicha, John Haughney, Katsiaryna Bichel, Daniel West

Research output: Contribution to journalArticle

10 Citations (Scopus)
4 Downloads (Pure)

Abstract

Clinical guidelines recommend long-acting bronchodilators as first maintenance therapy for chronic obstructive pulmonary disease (COPD), with inhaled corticosteroids (ICS) reserved for patients with more severe disease and exacerbations. The aim of this analysis was to examine real-life prescribing of first maintenance therapy for COPD in the UK. Data were extracted from the UK Optimum Patient Care Research Database for patients with a first prescription for COPD maintenance therapy between 2009 and 2012 and a diagnosis of COPD at or before the date of the first prescription for COPD maintenance therapy. Routine clinical data including demographics, disease history and symptoms, comorbidities, therapy, hospitalisation rate and exacerbation rate were collected and used to characterise patients stratified by disease severity and Global Initiative for Chronic Obstructive Lung Disease (GOLD) group (A-D). The analysis population included 2,217 individuals (55.4% male, 45.2% smokers). Long-acting muscarinic antagonists (LAMA) as monotherapy were prescribed as first maintenance therapy for 40.2% of patients. ICS were prescribed as ICS/long-acting beta-agonists combination for 29.1% of patients or as monotherapy for 15.5%. ICS (alone or in combination) were prescribed to >40% of patients in each GOLD group. ICS-containing regimens were prescribed to patients with a history of pneumonia and comorbid conditions for whom the risks of ICS therapy may outweigh the benefits. The clinical reality of prescribing indicates that ICS are often prescribed outside current guideline recommendations for many patients newly diagnosed with COPD in the UK. Encouragingly, LAMAs are increasingly being prescribed as first maintenance therapy for these patients.

Original languageEnglish
Article number16061
Journalnpj Primary Care Respiratory Medicine
Volume26
DOIs
Publication statusPublished - 3 Nov 2016

Fingerprint

Chronic Obstructive Pulmonary Disease
Databases
Adrenal Cortex Hormones
Therapeutics
Prescriptions
Guidelines
Muscarinic Antagonists
Bronchodilator Agents
Disease Progression
Comorbidity
Pneumonia
Patient Care
Hospitalization
Demography
Research
Population

Keywords

  • chronic obstructive pulmonary disease
  • therapeutics

Cite this

First maintenance therapy for COPD in the UK between 2009 and 2012 : a retrospective database analysis. / Price, David; Miravitlles, Marc; Pavord, Ian; Thomas, Mike; Wedzicha, Jadwiga; Haughney, John; Bichel, Katsiaryna; West, Daniel.

In: npj Primary Care Respiratory Medicine, Vol. 26, 16061, 03.11.2016.

Research output: Contribution to journalArticle

Price, David ; Miravitlles, Marc ; Pavord, Ian ; Thomas, Mike ; Wedzicha, Jadwiga ; Haughney, John ; Bichel, Katsiaryna ; West, Daniel. / First maintenance therapy for COPD in the UK between 2009 and 2012 : a retrospective database analysis. In: npj Primary Care Respiratory Medicine. 2016 ; Vol. 26.
@article{c1dacb7ced9f4e3d9684ff2cde9c89fd,
title = "First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis",
abstract = "Clinical guidelines recommend long-acting bronchodilators as first maintenance therapy for chronic obstructive pulmonary disease (COPD), with inhaled corticosteroids (ICS) reserved for patients with more severe disease and exacerbations. The aim of this analysis was to examine real-life prescribing of first maintenance therapy for COPD in the UK. Data were extracted from the UK Optimum Patient Care Research Database for patients with a first prescription for COPD maintenance therapy between 2009 and 2012 and a diagnosis of COPD at or before the date of the first prescription for COPD maintenance therapy. Routine clinical data including demographics, disease history and symptoms, comorbidities, therapy, hospitalisation rate and exacerbation rate were collected and used to characterise patients stratified by disease severity and Global Initiative for Chronic Obstructive Lung Disease (GOLD) group (A-D). The analysis population included 2,217 individuals (55.4{\%} male, 45.2{\%} smokers). Long-acting muscarinic antagonists (LAMA) as monotherapy were prescribed as first maintenance therapy for 40.2{\%} of patients. ICS were prescribed as ICS/long-acting beta-agonists combination for 29.1{\%} of patients or as monotherapy for 15.5{\%}. ICS (alone or in combination) were prescribed to >40{\%} of patients in each GOLD group. ICS-containing regimens were prescribed to patients with a history of pneumonia and comorbid conditions for whom the risks of ICS therapy may outweigh the benefits. The clinical reality of prescribing indicates that ICS are often prescribed outside current guideline recommendations for many patients newly diagnosed with COPD in the UK. Encouragingly, LAMAs are increasingly being prescribed as first maintenance therapy for these patients.",
keywords = "chronic obstructive pulmonary disease, therapeutics",
author = "David Price and Marc Miravitlles and Ian Pavord and Mike Thomas and Jadwiga Wedzicha and John Haughney and Katsiaryna Bichel and Daniel West",
note = "This research was conducted by Research in Real-Life Ltd (Cambridge, UK), an independent company. Medical writing support was provided by Tracey Lonergan on behalf of Complete Medical Communications and was funded by Almirall S.A. Funding This research was funded by Almirall S.A.",
year = "2016",
month = "11",
day = "3",
doi = "10.1038/npjpcrm.2016.61",
language = "English",
volume = "26",
journal = "npj Primary Care Respiratory Medicine",
issn = "2055-1010",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - First maintenance therapy for COPD in the UK between 2009 and 2012

T2 - a retrospective database analysis

AU - Price, David

AU - Miravitlles, Marc

AU - Pavord, Ian

AU - Thomas, Mike

AU - Wedzicha, Jadwiga

AU - Haughney, John

AU - Bichel, Katsiaryna

AU - West, Daniel

N1 - This research was conducted by Research in Real-Life Ltd (Cambridge, UK), an independent company. Medical writing support was provided by Tracey Lonergan on behalf of Complete Medical Communications and was funded by Almirall S.A. Funding This research was funded by Almirall S.A.

PY - 2016/11/3

Y1 - 2016/11/3

N2 - Clinical guidelines recommend long-acting bronchodilators as first maintenance therapy for chronic obstructive pulmonary disease (COPD), with inhaled corticosteroids (ICS) reserved for patients with more severe disease and exacerbations. The aim of this analysis was to examine real-life prescribing of first maintenance therapy for COPD in the UK. Data were extracted from the UK Optimum Patient Care Research Database for patients with a first prescription for COPD maintenance therapy between 2009 and 2012 and a diagnosis of COPD at or before the date of the first prescription for COPD maintenance therapy. Routine clinical data including demographics, disease history and symptoms, comorbidities, therapy, hospitalisation rate and exacerbation rate were collected and used to characterise patients stratified by disease severity and Global Initiative for Chronic Obstructive Lung Disease (GOLD) group (A-D). The analysis population included 2,217 individuals (55.4% male, 45.2% smokers). Long-acting muscarinic antagonists (LAMA) as monotherapy were prescribed as first maintenance therapy for 40.2% of patients. ICS were prescribed as ICS/long-acting beta-agonists combination for 29.1% of patients or as monotherapy for 15.5%. ICS (alone or in combination) were prescribed to >40% of patients in each GOLD group. ICS-containing regimens were prescribed to patients with a history of pneumonia and comorbid conditions for whom the risks of ICS therapy may outweigh the benefits. The clinical reality of prescribing indicates that ICS are often prescribed outside current guideline recommendations for many patients newly diagnosed with COPD in the UK. Encouragingly, LAMAs are increasingly being prescribed as first maintenance therapy for these patients.

AB - Clinical guidelines recommend long-acting bronchodilators as first maintenance therapy for chronic obstructive pulmonary disease (COPD), with inhaled corticosteroids (ICS) reserved for patients with more severe disease and exacerbations. The aim of this analysis was to examine real-life prescribing of first maintenance therapy for COPD in the UK. Data were extracted from the UK Optimum Patient Care Research Database for patients with a first prescription for COPD maintenance therapy between 2009 and 2012 and a diagnosis of COPD at or before the date of the first prescription for COPD maintenance therapy. Routine clinical data including demographics, disease history and symptoms, comorbidities, therapy, hospitalisation rate and exacerbation rate were collected and used to characterise patients stratified by disease severity and Global Initiative for Chronic Obstructive Lung Disease (GOLD) group (A-D). The analysis population included 2,217 individuals (55.4% male, 45.2% smokers). Long-acting muscarinic antagonists (LAMA) as monotherapy were prescribed as first maintenance therapy for 40.2% of patients. ICS were prescribed as ICS/long-acting beta-agonists combination for 29.1% of patients or as monotherapy for 15.5%. ICS (alone or in combination) were prescribed to >40% of patients in each GOLD group. ICS-containing regimens were prescribed to patients with a history of pneumonia and comorbid conditions for whom the risks of ICS therapy may outweigh the benefits. The clinical reality of prescribing indicates that ICS are often prescribed outside current guideline recommendations for many patients newly diagnosed with COPD in the UK. Encouragingly, LAMAs are increasingly being prescribed as first maintenance therapy for these patients.

KW - chronic obstructive pulmonary disease

KW - therapeutics

U2 - 10.1038/npjpcrm.2016.61

DO - 10.1038/npjpcrm.2016.61

M3 - Article

VL - 26

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

SN - 2055-1010

M1 - 16061

ER -